• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Cue Health, Major League Baseball partner on COVID-19 testing

Cue Health, Major League Baseball partner on COVID-19 testing

April 1, 2022 By Sean Whooley

Cue Health COVID-19 MLBCue Health (Nasdaq:HLTH) and Major League Baseball (MLB) announced today that will expand on league-wide COVID-19 testing.

Under a national partnership, Cue Health — MLB’s trusted at-home testing solution — will provide MLB clubs as well as the league office with its integrated care platform that includes the portable and reusable Cue Health monitoring system (reader) and the COVID-19 self-test.

Cue Health’s molecular COVID-19 test uses nucleic acid amplification technology (NAAT) to provide lab-quality results directly to connected mobile devices in 20 minutes, according to a news release. The company said its platform can detect all known COVID-19 variants of concern on users age 2 years old and up with or without symptoms.

“Major League Baseball, like other world-class organizations, continues to turn to Cue for testing when the stakes are high and when accuracy, speed, and reliability cannot be compromised,” Cue Health co-founder and CEO Ayub Khattak said in the release. “During their 2022 season, we will once again serve as MLB’s trusted at-home COVID-19 testing platform, providing the league with Cue’s actionable health information in real-time so players, teams, umpires, and officials can have the highest degree of confidence in the safety of their sport.”

The partnership also makes Cue Health a presenting sponsor of “Friday Night Baseball” on Apple TV+. The company also provides tests to other organizations, including the National Basketball Association (NBA) in sports, as well as Johns Hopkins Medicine, Mayo Clinic and Google, among others.

“After a great experience with Cue Health during the 2021 season and Postseason, we are thrilled to expand our utilization of the Cue platform and fully integrate the solution into our health and safety protocols for the 2022 season,” MLB VP of Drug, Health and Safety Programs Jon Coyles said. “We are highly confident that the speed, accuracy and portability of Cue’s COVID-19 self-test will help maximize our ability to successfully and safely complete the 2022 season as scheduled, and protect the health of our players and staff at our facilities, as well as their family members at home.”

Cue said it is working on new diagnostic tests that will be compatible with its reader platform.

Filed Under: Business/Financial News, Diagnostics, Genomics/Molecular Diagnostics, Health Technology Tagged With: coronavirus, COVID-19, Cue Health

More recent news

  • Vicarious Surgical inks surgical robot collab with hospital, eyes first clinical patients
  • Bioliberty launches hub for soft-robotic wearable devices
  • Zynex submits laser pulse oximeter to FDA
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub
  • Product liability lawsuits target Medtronic, Boston Scientific spinal cord stim tech

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy